A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action

Regulatory Peptides

Volumn 167, Issue 2-3, 2011, Pages 239-245

  Kim, Insoo ^a   Kim, Tae Hyung ^b   Ma, Kyungwan ^a   Park, Eun Seok ^b   Oh, Kyung Taek ^c   Lee, Eun Seong ^d   Lee, Kang Choon ^b   Youn, Yu Seok ^a  

^a Pusan National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Chung Ang University   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

4 arm PEG; Albumin binding; Exendin 4; PEGylation; Type 2 diabetes

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; EXENDIN 4; EXENDIN 4 PLUS MACROGOL PLUS PALMITYLAMINE CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERGLYCEMIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; GEL PERMEATION CHROMATOGRAPHY; MALE; MOLECULAR SIZE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ALBUMINS; ANIMALS; BINDING SITES; CELLS, CULTURED; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED ICR; PEPTIDES; POLYETHYLENE GLYCOLS; VENOMS;

MUS;

EID: 79953186889     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.02.008     Document Type: Article

References (30)

1. Kompella U.B., Lee V.H.L. Pharmacokinetics of peptide and protein drugs. Peptide and protein drug delivery 1991, 391-484. Marcel Dekker, New York. V.H.L. Lee (Ed.).
2. Caliceti P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003, 55:1261-1277.
3. Youn Y.S., Chae S.Y., Lee S., Jeon J.E., Shin H.G., Lee K.C. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol 2007, 73:84-93.
4. Harris J.M., Martin N.E., Modi M. Pegylation, a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001, 40:539-551.
5. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.
6. Sheffield W.P. Modification of clearance of therapeutic and potentially therapeutic proteins. Curr Drug Targets Cardiovasc Hematol Disord 2001, 1:1-22.
7. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
8. Bailon P., Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998, 1:352-356.
9. Lee S.H., Lee S., Youn Y.S., Na D.H., Chae S.Y., Byun Y., Lee K.C. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem 2005, 6:377-382.
10. Chae S.Y., Chun Y.G., Lee S., Jin C.H., Lee E.S., Lee K.C., Youn Y.S. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. J Pharm Sci 2009, 98:1556-1567.
11. Uchio T., Baudys M., Liu F., Song S.C., Kim S.W. Site-specific insulin conjugates with enhanced stability and extended action profile. Adv Drug Deliv Rev 1999, 35:289-306.
12. Chuang V.T., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002, 19:569-577.
13. Thibaudeau K., Léger R., Huang X., Robitaille M., Quraishi O., Soucy C., Bousquet-Gagnon N., van Wyk P., Paradis V., Castaigne J.-P., Bridon D. Synthesis and evaluation of insulin-human serum albumin conjugates. Bioconjug Chem 2005, 16:1000-1008.
14. Kim J.-G., Baggio L.L., Bridon D.P., Castaigne J.-P., Robitaille M.F., Jette L., Benquet C., Druker D.J. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003, 52:751-759.
15. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004, 53:2492-2500.
16. Baggio L.L., Huang Q., Cao X., Drucker D.J. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008, 134:1137-1147.
17. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., Ghatei M.A., Bloom S.R. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol 2005, 281:155-161.
18. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53:2181-2189.
19. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
20. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., Egan J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000, 141:1936-1941.
21. Davidson M.B., Bate G., Kirkpatrick P. Exenatide. Nat Rev Drug Discov 2005, 4:713-714.
22. Lee K.C., Chae S.Y., Kim T.H., Lee S., Lee E.S., Youn Y.S. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regul Pept 2009, 152:101-107.
23. Chae S.Y., Jin C.H., Shin J.H., Son S., Kim T.H., Lee S., Youn Y.S., Byun Y., Lee M.S., Lee K.C. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release 2010, 142:206-213.
24. Lee K.C., Tak K.K., Park M.O., Lee J.T., Woo B.H., Yoo S.D., Lee H.S., DeLuca P.P. Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. Pharm Dev Technol 1999, 4:269-275.
25. Shin B.S., Kim C.H., Lee M.N., Hur M.W., Lee K.C., Youn Y.S., Yoo S.D. Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration. Regul Pept 2006, 140:74-80.
26. Youn Y.S., Jung J.Y., Oh S.H., Yoo S.D., Lee K.C. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release 2006, 114:334-342.
27. Youn Y.S., Na D.H., Yoo S.D., Song S.C., Lee K.C. Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential. Int J Biochem Cell Biol 2005, 37:1525-1533.
28. Youn Y.S., Chae S.Y., Lee S., Kwon M.J., Shin H.J., Lee K.C. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. Eur J Pharm Biopharm 2008, 68:667-675.
29. Markussen J., Havelund S., Kurtzhals P., Andersen A.S., Halstrøm J., Hasselager E., Larsen U.D., Ribel U., Schäffer L., Vad K., Jonassen I. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996, 39:281-288.
30. Kim I., Kim T.H., Ma K., Lee E.S., Kim D., Oh K.T., Lee D.H., Lee K.C., Youn Y.S. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjug Chem 2010, 21:1513-1519.